- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00828620
Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project
August 9, 2012 updated by: Universitaire Ziekenhuizen KU Leuven
Imaging for Early Response Prediction to EGF-receptor Blocking Monoclonal Antibodies in Combination Therapy for Colorectal Cancer
Molecular imaging with positron emission tomography (PET) using [18F] fluorodeoxyglucose (FDG) has been suggested as an early, sensitive marker of tumour response to anticancer drugs by monitoring the changes in glucose metabolism in tumours.
Recently, FDG-PET has shown to be highly sensitive in detecting early response in other tumours.
In this study, the investigators will prospectively investigate the role of early FDG-PET (at day 7 and week 6) in outcome prediction.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
21
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerpen, Belgium
- ZNA Middelheim
-
Kortrijk, Belgium
- AZ Groeninge
-
Leuven, Belgium, 3000
- UZLeuven
-
Menen, Belgium
- H Hart Roeselare Campus menen
-
Roeselare, Belgium
- Stedelijk Ziekenhuis Roeselare
-
Wilrijk, Belgium
- Sint Augustinus Ziekenhuis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
unresectable stage IV colorectal cancer pathologically proven measurable disease (RECIST) K-RAS wild type Eligible for 3rd line Irinotecan + Cetuximab Able for tolerate PET/CT imaging Serum glucose < 200mg/dl
Description
Inclusion Criteria:
- Histologically or cytologically proven colorectal cancer
- Unresectable stage IV disease
- K-Ras wild type tumour
- Patients scheduled to undergo chemotherapy with irinotecan and cetuximab
Exclusion Criteria:
- Prior abdominal/pelvic radiotherapy, surgery or chemotherapy within 3 months prior to inclusion in the study
- Poorly controlled diabetes
- Concomitant serious illness, such as uncontrolled angina pectoris, myocardial infarction, heart failure, uncontrolled hypertension, infection
- Symptomatic brain metastases
- Pregnancy or participants of reproductive potential who are sexually active and not willing/able to use medically appropriate contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PET-CT
Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
|
PET-CT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PET response on day 7
Time Frame: day 7
|
day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine whether the PET criteria for response on day 7 correlates with the CT criteria of minimum 10% decrease in tumour size (RECIST) at week 6
Time Frame: week 6
|
week 6
|
To define the optimal cutoff value of SUVmax and their predictive value
Time Frame: at day 7 and week 6
|
at day 7 and week 6
|
To explore the test/retest reliability of PET/CT in this setting
Time Frame: 2 weeks
|
2 weeks
|
To assess the value of PET/CT at day 7 in predicting overall survival
Time Frame: up to 1 year
|
up to 1 year
|
To asses the correlations between biomarkers and PET changes after Cetuximab
Time Frame: up to 6 months
|
up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Eric Van Cutsem, Prof.Dr, UZ Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
January 23, 2009
First Submitted That Met QC Criteria
January 23, 2009
First Posted (Estimate)
January 26, 2009
Study Record Updates
Last Update Posted (Estimate)
August 10, 2012
Last Update Submitted That Met QC Criteria
August 9, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- s51276 - ML5241
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on Imaging study
-
Mayo ClinicNational Cancer Institute (NCI)CompletedVibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast CancerBreast CancerUnited States
-
Seoul National University HospitalActive, not recruitingBreast Cancer | Surgery | Chemotherapy Effect | IMAGEKorea, Republic of
-
National Eye Institute (NEI)CompletedMacular Degeneration | Diabetic Retinopathy | Mitochondria | Hippel-Landau DiseaseUnited States
-
University of CalgaryCompleted
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)CompletedBreast CancerUnited States, Canada, Argentina
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonTerminatedCRT In Narrow QRS Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical MappingHeart FailureUnited Kingdom
-
Lumicell, Inc.National Cancer Institute (NCI); Massachusetts General HospitalTerminatedBreast Cancer | Neoadjuvant TherapyUnited States
-
Lumicell, Inc.National Cancer Institute (NCI)Completed
-
Seno Medical Instruments Inc.Completed